Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02773030 · ClinicalTrials.gov registry record · Phase 1

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by Celgene.

Active
Registry status
Phase 1
Development phase
466
Enrollment target
20
Study locations

NCT02773030: Active Phase 1 study of Multiple Myeloma, sponsored by Celgene.

NCT02773030 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Celgene. The registered enrollment target is 466 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (15% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02773030, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Celgene.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
466 participants
Enrollment target
20
Study locations

Study Summary

This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.

Primary Outcome

The dose-limiting toxicity (DLT) population includes subjects who missed no more than 4 doses of CC-220, 2 doses of DEX, 1 dose of IV DARA (Cohort E), 1 dose of BTZ (Cohort F), or 1 dose of CFZ (Cohort G1 or G2) during Cycle 1 for reasons other than DLT. This population will be used for analyzing the primary endpoint regarding the determination of the MTD. Hematologic DLTs: Grade 4 neutropenia (ANC \<500/μL for \>5 days) Grade 3 neutropenia (ANC \<1,000/μL) with fever ≥38.5°C Grade 4 thrombocy

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Daratumumab
  • DRUG Carfilzomib
  • DRUG Bortezomib
  • DRUG CC-220

Study Locations (20)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Local Institution - 114 - Boston
  • Local Institution - 115 - Boston
  • Massachusetts General Hospital - Boston
  • Dana-Farber/Mass General Brigham Cancer Care, Inc - Boston
  • Local Institution - 110 - Boston

Arizona

  • Local Institution - 102 - Scottsdale
  • Mayo Clinic - Scottsdale

Arkansas

  • Local Institution - 107 - Little Rock
  • University of Arkansas for Medical Sciences - Little Rock

Georgia

  • Local Institution - 101 - Atlanta
  • Winship Cancer Institute of Emory University - Atlanta

Illinois

  • Local Institution - 120 - Chicago
  • Robert H Lurie Comprehensive Cancer Center NW Univ - Chicago

Kansas

  • Local Institution - 113 - Fairway
  • University of Kansas Cancer Center - Fairway

Maryland

  • Local Institution - 106 - Baltimore
  • University of Maryland School of Med - Baltimore

Michigan

  • Local Institution - 104 - Ann Arbor
  • University of Michigan Comprehensive Cancer Center - Ann Arbor

Trial Details

FieldValue
Enrollment Target 466 participants
Start Date 2016-10-14
Est. Completion 2028-07-28
Phase Phase 1
Celgene

308 total trials

What the registry record for NCT02773030 still lists

NCT02773030 is an interventional study that assigns participants to a tested intervention. The registered 466 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (15% lower).

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.

NCT02773030 names 20 study sites across 8 states, led by Massachusetts, Arizona, Arkansas.

Frequently Asked Questions

What is clinical trial NCT02773030 about?

NCT02773030 is a clinical study titled "A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma". This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with...

What is the current status of trial NCT02773030?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 466 participants. The study started on 2016-10-14. Estimated completion is 2028-07-28.

What conditions does trial NCT02773030 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT02773030?

The interventions under investigation include: Dexamethasone (DRUG), Daratumumab (DRUG), Carfilzomib (DRUG), Bortezomib (DRUG), CC-220 (DRUG).

Who is sponsoring clinical trial NCT02773030?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02773030 being conducted?

This trial has 20 study locations across Arizona, Arkansas, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02773030's enrollment target sits among peer trials

466 51st of 438 higher than 388 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05312879 · 466 participants · Phase 2

    Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease

  • NCT06917404 · 466 participants · Phase 3

    A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.

  • NCT07055165 · 466 participants · NA

    Connect2Care: Prostate Cancer Education and Screenings for African American Men

  • NCT07214779 · 466 participants · Phase 3

    Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02773030, the US trial registry maintained by the National Library of Medicine. NCT02773030 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.